The aim of the division of Systems Biomedicine and Pharmacology lies in the development of personalised medicine strategies, and development of new systems-based approaches in translational and clinical pharmacology.

Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh

System Biomedicine and Pharmacology consists of 120 European Credit Transfer System (EC) points.

Cluster contact information & address

Key publications of the Systems Pharmacology group

The present thesis focuses on the pharmacological concept of drug-target interaction, which dates back to the beginning of modern pharmacology.

MHC class I and MHC class II molecules present peptides to the immune system to drive proper T cell responses. Pharmacological modulation of T-cell responses can offer treatment options for a range of immune-related diseases.

The System Biomedicine and Pharmacology specialisation consists of compulsory and optional components.

Key publications of the Quantitative Pharmacology group

Promotie

Promotie

Promotie

During the course of drug discovery translational steps are made.

Key publications of the Predictive Pharmacology group.

Key publications of the Quantitative Clinical Pharmacology group

Congres/symposium

Pharmacokinetic studies in obese adolescents and obese adults

Do you have questions about the System Biomedicine and Pharmacology master’s programme? Please contact us.

How do genetic and environmental factors make us vulnerable to depression?

Promotor: Prof.dr. A. P. IJzerman, Co-Promotor: Dr. L.H. Heitman

Drug development is a time- and resource-consuming process that starts with the discovery and validation of a (protein) target that contributes to pathogenesis or disease progression.

The main aim of my Ph.D. thesis is to further explore the value of using early developing zebrafish larvae (up to 5 dpf) as a model to study anxiety-like behaviour and their pharmacological modulation with drugs.

An overview of research themes and projects at ABS.

The Leiden Academic Centre for Drug Research (LACDR) is a centre of excellence for multidisciplinary research on drug discovery and development.

The master’s programme of Bio-Pharmaceutical Sciences at Leiden University examines the research area of bio-pharmaceutical sciences and drug research. It offers seven specialisations ranging from BioTherapeutics to Industrial Pharmacy.

Promotie

Promotie

Promotie

The list of substances prohibited by the World Anti-Doping Agency (WADA) is huge. PhD candidate Jules Heuberger looked at many of these, as well as at the methods used to detect them. He concluded that for very few of these substances is there is evidence that they actually do enhance performance. PhD…

Within the Chinese medicine, more than 80% of the constituents of the preparations are derived from plants. Like any other organism, plants are constantly interacting with their changing and often harsh environment during the various phases of their life cycle.

What are the biological effects of Chinese herbal medicine in regulation of cancer cell metastasis?

Find out how to apply for System Biomedicine and Pharmacology at Leiden University by following our step-by-step guide.

The aim of this project is to explore the use of statistical interaction models to quantify cross-omics and omics-drug interactions in large-scale clinical and experimental datasets

The Leiden Academic Centre for Drug Research (LACDR) is responsible for the research and education in Bio-Pharmaceutical Sciences carried out at Leiden University.

We have developed a microfluidic platform for complex 3D organotypic cell cultures (so-called organ-on-a-chip systems) which are suited for integration in 96 or higher well plate format.

The brain is a complex organ, and researching medicine to treat brain disorders is equally if not more complex. Elizabeth (Liesbeth) de Lange, Professor of Predictive Pharmacology, calls for a structured approach. ‘In effect, it's like playing Mastermind.’ Inaugural lecture on 22 March.

How does stress influence cognitive performance? What is the role of selective attention to threatening information in this effect? Could we prevent stress-induced decline of cognitive performance with pharmacological interventions? Could we use resting state theta/beta ratio as a biomarker for cognitive…

The distinction of outstanding and rewarded scientific and educational achievements is an important component of the promotion of our work at the LACDR.

.

Research in the BioTherapeutics research programme is aimed at a smoother and speedier transition from preclinical research to pharmacological interventions, and the delivery of drugs in the human body by use of small molecules and biologics.

Another research line is the development of a spatial CNS drug distribution model, by ultimately including the 3-dimensional anatomical organization of the CNS.

The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.

The two-years MSc programme spans the entire spectrum of Analytical BioSciences, Biopharmaceutics, Drug Delivery Technology, Medicinal Chemistry, Pharmacology and Toxicology.

The need for novel drugs as well as innovations in their development and application is as urgent as ever. Below we present our vision , mission, and our key research areas.

Key publications of the Medical Systems Biophysics and Bioengineeringgroup (Mashaghi Lab)

The factors that dynamically sculpt the inter-regional correlation of brain patterns are poorly understood. Here, we test the hypothesis that they are shaped by the catecholaminergic neuromodulators norepinephrine and dopamine.

Knowledge on how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, obese individuals or critically-ill patients, is not only crucial for novel compounds, but also for existing drugs which are often used in an off-label manner in these special patient…

The lack of success of new CNS drugs in clinical development is in part due to the complexity of the CNS, unexpected side effects, difficulties for drugs to penetrate the brain, but also by the lack of biomarkers.

A research goal for ABS is to develop miniaturized platforms for research in (stem)cell, in-vitro systems and application in clinical and preventive research. Combined with the high throughput, this development will make it possible to study the dynamics of pathogenesis in human and cellular models…